BJMO - 2024, issue Special, february 2024
J. Blokken PhD, PharmD
In line with the tradition, the 2024 annual BSMO meeting kicked off with a session from the Breast Cancer Task Force. Dr. Françoise Derouane (University Hospitals Leuven, Leuven) opened the session with a lecture on candidates for neoadjuvant chemotherapy in luminal disease. Thereafter, Dr. Ines Nevelsteen (University Hospitals Leuven, Leuven) discussed targeted axillary dissection after neoadjuvant chemotherapy in cN+ disease. In a third lecture, Dr. Nuria Kotecki (Institut Jules Bordet, Brussels) addressed the current challenges in the approach of brain metastases in breast cancer. Finally, Dr. Kevin Punie (GZA Hospitals Sint-Augustinus, Wilrijk) shared his knowledge and experience on how to select the optimal adjuvant endocrine therapy in early HR+ breast cancer.
Read moreBJMO - 2024, issue Special, february 2024
A. Enguita PhD, T. Feys MBA, MSc
During the 2024 BSMO annual meeting, an entire session was dedicated to the recent advances in the treatment of gynaecological cancers. In a first lecture of this session, Prof. Dr. Christine Gennigens (CHU de Liège) gave an overview of the contemporary treatment landscape for patients with cervical cancer, after which Prof. Dr. Hannelore Denys (University Hospital Ghent), summarised the recent treatment advances and clinical updates in the treatment of endometrial cancer. To wrap up the session, Prof. Jean-François Baurain (UCLouvain) took the stage to provide an overview of the latest findings in the management of ovarian cancer.
Read moreBJMO - 2024, issue Special, february 2024
J. Blokken PhD, PharmD
The second day of the 2024 annual BSMO meeting kicked off with a session from the supportive care task force. First, Dr. Gary Deng (Memorial Sloan Kettering Cancer Center, United States) gave a talk on integrative medicine and how it helps cancer supportive care. Thereafter, Dr. Antonietta Iasiello (Dr. Spinedi Clinic, Orselina, Switzerland), discussed health education according to the Charter of Ottawa.
Read moreBJMO - 2024, issue Special, february 2024
J. Collins PhD
At the BMSO Annual Meeting 2024, Dr. Peter Vuylsteke (Medical Oncologist and Head of Department Internal Medicine at the University of Botswana) discussed the treatment disparities in oncological care and provided some suggestions on how to bridge this gap.1 Dr. Vuylsteke began by highlighting that not only is there a disparity in care between low- and middle-income countries (LMIC) and high-income countries (HIC), but disparities also arise due to the outbreak of war and epidemics such as COVID-19. Finally, regional differences in the quality of care exist.
Read moreBJMO - 2024, issue Special, february 2024
A. Enguita PhD
During the ‘What you should not have missed’ session at this year’s BSMO meeting, Prof. Dr. Awada from the Jules Bordet Institute revisited key treatment advances and clinical updates in oncology from 2023.
Read moreBJMO - 2024, issue Special, februari 2024
T. Feys MBA, MSc
The 2023 edition of the San Antonio Breast Cancer Symposium featured the presentation of long-term follow-up data of the KATHERINE trial, confirming the long-term invasive disease free and overall survival benefit of T-DM1 over trastuzumab in patients with HER2+ breast cancer and residual disease after neoadjuvant therapy. 1 In advanced HER2-positive breast cancer, HER2CLIMB02 showed that adding tucatinib to T-DM1 delays disease progression in previously treated patients, irrespective of the presence of brain metastases.2 In addition, a phase II study showed a progression-free survival benefit for the addition of avelumab to vinorelbine and trastuzumab in heavily pre-treated patients with HER2+ metastatic breast cancer.3 Finally, first-line T-DM1 was found to be less effective than trastuzumab-pertuzumab-docetaxel in older patients with HER2+ advanced breast cancer although it did come with a lower toxicity burden.4
Read moreBJMO - 2024, issue Special, februari 2024
James Collins PhD, T. Feys MBA, MSc
With respect to hormone receptor positive (HR+) breast cancer, SABCS 2023 featured subgroup analyses of the CheckMate 7FL and KEYNOTE-756 trials evaluating perioperative nivolumab or pembrolizumab in patients with early-stage disease.1,2 Also in early-stage HR+ breast cancer, the final invasive disease free survival (iDFS) analysis of the NATALEE trial was presented evaluating adjuvant ribociclib added to ET.3 In metastatic HR+/HER2- breast cancer, datopotamab deruxtecan was shown to delay disease progression in pre-treated patients.4 In the first line treatment for advanced HR+/HER2- breast cancer, SABCS 2023 featured the overall survival (OS) analysis of the MONARCH-3 trial, while INAVO120 demonstrated a progression-free survival (PFS) benefit for the addition of the PI3Kα inhibitor inavolisib to palbociclib and fulvestrant in patients with PIK3CA-mutated, HR+/HER2- advanced breast cancer.5
Read more
Top
